An announcement from Dr Reddy’s Laboratories ( (RDY) ) is now available.
On February 28, 2025, Dr. Reddy’s Laboratories received an order from the Excise and Taxation Officer in Ambala, Haryana, regarding a tax demand under the HGST Act, 2017. The order includes a penalty of Rs. 38,63,481 due to irregular credit on sales returns. Despite the penalty, the company has assessed that there is no material impact on its financials or operations. Dr. Reddy’s is considering filing an appeal against this order.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a pharmaceutical company based in Hyderabad, India. It is involved in the manufacturing and marketing of a wide range of pharmaceutical products and services, focusing on generic medications and active pharmaceutical ingredients.
YTD Price Performance: -18.44%
Average Trading Volume: 1,860,237
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $10.66B
For an in-depth examination of RDY stock, go to TipRanks’ Stock Analysis page.